Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vir Biotechnology ( (VIR) ) just unveiled an update.
On December 16, 2025, Vir Biotechnology entered into a license agreement with Norgine Pharma UK Limited, granting Norgine exclusive commercial rights to a combination treatment for chronic hepatitis delta (CHD) in Europe, Australia, and New Zealand. Vir will receive an initial EUR 55 million reimbursement and up to EUR 495 million in milestones, with shared clinical development costs for ongoing trials. The combination treatment of tobevibart and elebsiran showed promising results in a Phase 2 trial, achieving significant virologic suppression and being well-tolerated, which could enhance Vir’s market positioning and impact stakeholders positively.
The most recent analyst rating on (VIR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.
Spark’s Take on VIR Stock
According to Spark, TipRanks’ AI Analyst, VIR is a Neutral.
Vir Biotechnology’s overall stock score is primarily impacted by its financial performance, which is currently weak due to declining revenues and profitability issues. While technical analysis shows positive momentum, the valuation remains unattractive due to ongoing losses. The earnings call provided some optimism with progress in clinical programs and a strong cash position, but financial challenges persist.
To see Spark’s full report on VIR stock, click here.
More about Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer. Its portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers for solid tumor indications, along with preclinical programs for various infectious diseases and oncologic malignancies.
Average Trading Volume: 1,543,517
Technical Sentiment Signal: Hold
Current Market Cap: $930.7M
Learn more about VIR stock on TipRanks’ Stock Analysis page.